The global inhalation and nasal spray generic drugs market size was surpassed at USD 17.8 billion in 2021 and is projected to hit around USD 39.6 billion by 2030 with a CAGR of 8.96% from 2022 to 2030.
The market is primarily driven by the rising incidence of chronic respiratory diseases globally. According to the Global Asthma Report, nearly 330 million people have asthma worldwide and this number is expected to reach more than 400 million cases by 2025. Increasing tobacco use, air pollution, and smoking are some of the major causes leading to rising asthma cases globally.
Increasing geriatric population, coupled with its increased susceptibility to chronic respiratory diseases, is expected to drive the market. As per the WHO estimates, 1 out of 6 people will be aged 6o years and above worldwide by 2030. Furthermore, the world population of such individuals is estimated to reach 2.1 billion by 2050. Moreover, the Asthma & Allergy Foundation of America states that about 7.8% of the U.S. population aged 65 and older had asthma in 2020.
Key players such as Cipla Inc.; Teva Pharaceuticals; and Viatris Inc. are focusing on new product developments and launches. Increasing number of generic inhalation and nasal spray product approvals for the treatment of respiratory diseases including asthma, COPD, and allergic rhinitis is anticipated to fuel market growth. For instance, in March 2022, Mylan Pharmaceuticals, a Viatris Inc. subsidiary, received FDA approval for ANDA for inhalation aerosol Breyna, a generic version of Symbicort indicated for asthma and COPD patients. This approval supports the company’s objective of launching Breyna in 2022.
However, the regulatory obstructions due to stringent laws for the sales of generic drugs in countries such as Mexico and Russia are expected to hamper the market growth. For instance, COFEPRIS, the regulatory authority of Mexico, announces new guidelines for granting registrations of generic drugs, which will not include patents of new therapeutic uses in its linkage system. Furthermore, COFEPRIS exercises a special procedure window for generic pharmaceutical products in Mexico.
Drug Class Insights
The bronchodilators segment accounted for the largest revenue share of over 25.0% in 2021 owing to its high adoption for the treatment of respiratory diseases including asthma and COPD worldwide. The rising prevalence of asthma and COPD is further driving the segment. As stated by the WHO, in 2019, around 262 million people were suffering from asthma. Also, according to the Asthma and Allergy Foundation of America, in 2020, 1 in every 13 people, which is nearly 25 million U.S. people, had asthma. Thus, rise in the use of bronchodilators is expected to drive the market.
The combination drugs segment is expected to expand at the fastest CAGR of 9.85% during the forecast period. This growth is attributed to the launch of combination drugs by key players including Apotex Inc. and Teva Pharmaceutical Industries Ltd. For instance, in March 2020, Apotex Inc. launched a generic version of Meda Pharmaceuticals’ Dymista (a combination drug of azelastine and fluticasone) nasal spray used for the treatment of allergic rhinitis.
Patient Demographics Insights
The adult patient segment accounted for the largest revenue share of over 40.0% in 2021. Rising number of adult patients suffering from asthma and COPD is the major factor contributing to the segment growth. According to the CDC, among total asthmatic patients, around 60% are aged between 18 and 65. Also, according to the European Respiratory Society, females are more likely to develop asthma throughout their lifetime than males. Moreover, asthma is almost twice as prevalent in females aged 18 and above than adult males. According to the CDC, nearly 13.5 million women were affected with asthma in comparison to 7.4 million men in the U.S. in 2020.
The pediatric patient segment is expected to grow during the forecast period owing to the rising use of inhalers for the treatment of cystic fibrosis, asthma, and chronic lung disease in children. Rising government initiatives for childhood asthma awareness programs boost the adoption of inhalers. For instance, the National Childhood Asthma Media Campaign is designed in association with the Ad Council to increase awareness regarding the prevention and management of asthma.
End-user Insights
The homecare segment accounted for the largest revenue share of over 50.0% in 2021 owing to favorable reimbursement policies and growing elderly population. Home care involves the management of respiratory disorders at the residence of patients and homecare facilities. Rising healthcare awareness and product advancement allow patients to use inhalers and nasal sprays at home without the assistance of medical professionals. Also, increasing geriatric population further boosts the segment growth. According to the WHO, 1 billion were aged 60 years and more in 2020 and this number will increase to 1.4 billion by 2030 and 2.1 billion by 2050, worldwide.
The homecare segment is expected to expand at the fastest CAGR during the forecast period. Rising awareness regarding the management and prevention of asthma attacks in children and adult patients is boosting the segment growth. Also, the usage of inhalers at home for the management of asthma, COPD, and other respiratory diseases has grown significantly owing to government support, awareness programs, and rising healthcare spending. For instance, in the U.S., CDC’s National Asthma Control Program helps people with asthma to achieve a better quality of life.
Distribution Channel Insights
Retail pharmacies accounted for the largest revenue share of over 55.0% in 2021 due to increasing healthcare expenditure and high generic drug sales. For instance, in 2019, generic drugs accounted for about 90% of prescription drugs dispensed in the U.S. Moreover, on average, the gross margin of generics in pharmacies is approximately 43% indicating high revenue. In addition, overall pharmaceutical expenditure has increased through the years. For instance, the expenditure on pharmaceuticals in the U.S. grew by 4.9% from 2019 to 2020.
The online pharmacies segment is expected to grow during the forecast period. Online pharmacies offer ease of access and convenience to patients. With increase in internet penetration, the number of users purchasing online pharmacy products is increasing rapidly. For instance, in 2020, the number of products dispensed from online pharmacies increased by about 45% from the previous year in England.
Indication Insights
The asthma segment accounted for the largest revenue share of over 40.0% in 2021 owing to the increased prevalence of asthma attacks among children and adults. As per the National Health Interview Survey under the CDC, around 10.3 million children aged 18 and below and adults encountered asthma attacks in 2020 in the U.S., which accounted for 41% of cases. Moreover, in 2019, the rate of emergency department visits for asthma increased by nearly 57%.
The Chronic Obstructive Pulmonary Disease (COPD) segment is anticipated to grow during the forecast period owing to the launch of new products and rising demand for generics for the treatment of COPD. For instance, in January 2019, Mylan N.V.’s WixelaInhub, a generic counterpart of Advair Diskus, was granted FDA approval for treating COPD and asthma. Such approvals are expected to accelerate market growth.
Regional Insights
North America dominated the market with a revenue share of over 35.0% in 2021. The launch of new products, acquisitions and partnerships, and increased prevalence of chronic respiratory diseases are the major factors fueling the regional growth. According to the CDC, the prevalence of chronic obstructive pulmonary disease (COPD) in the U.S. is 57 per 100,000 in men and 40.5 per 100,000 among women. The launch of generic versions of nasal sprays is expected to fuel market growth. For instance, in December 2021, Sandoz launched a generic form of Narcan (naloxone HCl) Nasal Spray indicated for opioid overdose reversal in the U.S.
Asia Pacific is expected to register a lucrative CAGR of 11.23% during the forecast period. The growth of the region is attributed to the strategic partnerships to manufacture generic products in the region. For instance, in August 2021, CDMO Bora Pharmaceuticals Laboratories Inc. partnered with Kyowa Pharmaceuticals Industry Co. Ltd. to manufacture generic products, including nasal sprays, in Japan. This contract strengthens and increased visibility of Taiwan’s pharmaceutical capabilities.
Some prominent players in the global inhalation and nasal spray generic drugs market include:
Teva Pharmaceuticals Industries Ltd.
Mylan N.V.
Akorn, Operating Company LLC
Cipla Inc.
Sandoz International GmBH (Novartis AG)
Apotex Inc.
Hikma Pharmaceuticals PLC
Sun Pharmaceuticals Industries Ltd.
Beximco Pharmaceuticals Ltd.
Nephron Pharmaceuticals Corporation
Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Bronchodilators
Combination Drugs
Corticosteroids
Decongestant Sprays
Antihistamines
Others
Indication Outlook (Revenue, USD Million, 2018 - 2030)
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Allergic Rhinitis
Others
Patient Demographics Outlook (Revenue, USD Million, 2018 - 2030)
Geriatric Patient
Adult Patient
Pediatric Patient
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Homecare
Others
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
Australia
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
MEA
South Africa
Saudi Arabia
UAE
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Inhalation And Nasal Spray Generic Drugs Market
5.1. COVID-19 Landscape: Inhalation And Nasal Spray Generic Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Inhalation And Nasal Spray Generic Drugs Market, By Drug Class
8.1. Inhalation And Nasal Spray Generic Drugs Market, by Drug Class, 2022-2030
8.1.1. Bronchodilators
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Combination Drugs
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Decongestant Sprays
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Antihistamines
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Inhalation And Nasal Spray Generic Drugs Market, By Indication
9.1. Inhalation And Nasal Spray Generic Drugs Market, by Indication, 2022-2030
9.1.1. Asthma
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Chronic Obstructive Pulmonary Disease (COPD)
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Allergic Rhinitis
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Inhalation And Nasal Spray Generic Drugs Market, By Patient Demographics
10.1. Inhalation And Nasal Spray Generic Drugs Market, by Patient Demographics, 2022-2030
10.1.1. Geriatric Patient
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Adult Patient
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Pediatric Patient
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Inhalation And Nasal Spray Generic Drugs Market, By End-user
11.1. Inhalation And Nasal Spray Generic Drugs Market, by End-user, 2022-2030
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Homecare
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Inhalation And Nasal Spray Generic Drugs Market, By Distribution Channel
12.1. Inhalation And Nasal Spray Generic Drugs Market, by Distribution Channel, 2022-2030
12.1.1. Hospitals Pharmacy
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Retail Pharmacy
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Inhalation And Nasal Spray Generic Drugs Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.2. Market Revenue and Forecast, by Indication (2020-2032)
13.1.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.1.4. Market Revenue and Forecast, by End-user (2020-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Indication (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.1.6.4. Market Revenue and Forecast, by End-user (2020-2032)
13.1.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.8.2. Market Revenue and Forecast, by Indication (2020-2032)
13.1.8.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.1.8.4. Market Revenue and Forecast, by End-user (2020-2032)
13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.2. Market Revenue and Forecast, by Indication (2020-2032)
13.2.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.2.4. Market Revenue and Forecast, by End-user (2020-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.2.7. Market Revenue and Forecast, by End-user (2020-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Indication (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.2.10. Market Revenue and Forecast, by End-user (2020-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Indication (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.2.12.4. Market Revenue and Forecast, by End-user (2020-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Indication (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.2.14.4. Market Revenue and Forecast, by End-user (2020-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.2. Market Revenue and Forecast, by Indication (2020-2032)
13.3.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.3.4. Market Revenue and Forecast, by End-user (2020-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.3.6.4. Market Revenue and Forecast, by End-user (2020-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Indication (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.3.8.4. Market Revenue and Forecast, by End-user (2020-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Indication (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.3.10.4. Market Revenue and Forecast, by End-user (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Indication (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.3.11.4. Market Revenue and Forecast, by End-user (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.2. Market Revenue and Forecast, by Indication (2020-2032)
13.4.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.4.4. Market Revenue and Forecast, by End-user (2020-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.4.6.4. Market Revenue and Forecast, by End-user (2020-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Indication (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.4.8.4. Market Revenue and Forecast, by End-user (2020-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Indication (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.4.10.4. Market Revenue and Forecast, by End-user (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Indication (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.4.11.4. Market Revenue and Forecast, by End-user (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.2. Market Revenue and Forecast, by Indication (2020-2032)
13.5.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.5.4. Market Revenue and Forecast, by End-user (2020-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Indication (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.5.6.4. Market Revenue and Forecast, by End-user (2020-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Indication (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Patient Demographics (2020-2032)
13.5.8.4. Market Revenue and Forecast, by End-user (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Teva Pharmaceuticals Industries Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Mylan N.V.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Akorn, Operating Company LLC
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Cipla Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Sandoz International GmBH (Novartis AG)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Apotex Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Hikma Pharmaceuticals PLC
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceuticals Industries Ltd.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Beximco Pharmaceuticals Ltd.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Nephron Pharmaceuticals Corporation
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers